These top hits highlight both expected and underexplored targets consistently altered in AD plasma across cohorts, including those with established ties to lipid metabolism (APOB and GPD1), cholinergic signaling and/or treatment response (ACHE and VAT1) and synaptic integrity (NPTXR), as well as novel targets linked to cytoskeletal regulation (ARPC2) and RNA metabolism (PA2G4 and RPS12). The gene discussed is APOB; the disease is Alzheimer disease.